Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 28, 2023
Daily News
September 28, 2023
- Lilly Japan to Build New Manufacturing Facility, Eyes Mounjaro Supply Boost
September 28, 2023
- Mundipharma Files Anesthetic Med Anerem for New Indication in Japan
September 28, 2023
- MHLW Expert Panel Draws Up New Cancer Research Strategy
September 28, 2023
- Assess Evaluation Methods for Innovative Medical Products: Science Council
September 28, 2023
- As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
- Japan PM Asks Health Minister to Reform Pricing of Potential Blockbusters
September 28, 2023
- Sawai’s Revlimid Generic Gets MDS Nod; December Listing Eyed
September 28, 2023
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Ex-Senior Vice Minister Koga to Lead LDP’s Health Division
September 28, 2023
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
- Ono, Adimab Join Hands to Discover Antibody Drugs for Cancer
September 28, 2023
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…